Fondaparinux Sodium Injection, Solution
NDC Package 55150-232-02

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Fondaparinux Sodium injection is fondaparinux is used to treat serious blood clots in the legs and/or lungs. This formulation utilizes a injection, solution delivery system. Marketed by Eugia Us Llc, this product is identified by NDC 55150-232 and is authorized under FDA application ANDA206918.

Identification & Billing

NDC Package Code
55150-232-02
Package Description
2 SYRINGE, GLASS in 1 CARTON / .6 mL in 1 SYRINGE, GLASS (55150-232-00)
Product Code
55150-232
11-Digit Billing Format
55150023202
RxNorm Crosswalk
  • RxCUI: 861356 - fondaparinux sodium 10 MG in 0.8 ML Prefilled Syringe
  • RxCUI: 861356 - 0.8 ML fondaparinux sodium 12.5 MG/ML Prefilled Syringe
  • RxCUI: 861356 - fondaparinux sodium 10 MG per 0.8 ML Prefilled Syringe
  • RxCUI: 861360 - fondaparinux sodium 2.5 MG in 0.5 ML Prefilled Syringe
  • RxCUI: 861360 - 0.5 ML fondaparinux sodium 5 MG/ML Prefilled Syringe

Clinical Specifications

Proprietary Name
Fondaparinux Sodium
Non-Proprietary Name
Fondaparinux Sodium
Substance Name
Fondaparinux Sodium
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Active Ingredient(s)
FONDAPARINUX SODIUM 7.5 mg/.6mL
Pharmacologic Class
Usage Information
Fondaparinux is used to treat serious blood clots in the legs and/or lungs. It is usually used with another "blood thinner" medication (warfarin). If untreated, blood clots can travel to the lungs, heart, or brain, causing serious (possibly fatal) breathing problems, heart attack, or stroke. This drug may also be used to prevent blood clots after certain surgeries with an increased risk of blood clots (such as hip fracture, abdominal, knee/hip replacement). Fondaparinux is known as a "blood thinner" (anticoagulant). It is a drug similar to heparin that works by blocking certain natural substances in the blood that cause clotting.

Regulatory & Marketing

Labeler Name
Eugia Us Llc
Product Type
Human Prescription Drug
FDA Application #
ANDA206918
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
12-26-2017
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (55150-232). Click a package code to view its specific billing and regulatory data.

55150-232-10
10 SYRINGE, GLASS in 1 CARTON / .6 mL in 1 SYRINGE, GLASS (55150-232-00)

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 55150-232-02 identifies a specific commercial package of 2 syringe, glass in 1 carton / .6 ml in 1 syringe, glass (55150-232-00) of Fondaparinux Sodium, a human prescription drug labeled by Eugia Us Llc. This injection, solution is formulated for subcutaneous use and contains fondaparinux sodium as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Eugia Us Llc on December 26, 2017. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Fondaparinux is used to treat serious blood clots in the legs and/or lungs. It is usually used with another "blood thinner" medication (warfarin). If untreated, blood clots can travel to the lungs, heart, or brain, causing serious (possibly fatal) breathing problems, heart attack, or stroke. This drug may also be used to prevent blood clots after certain surgeries with an increased risk of blood clots (such as hip fracture, abdominal, knee/hip replacement). Fondaparinux is known as a "blood thinner" (anticoagulant). It is a drug similar to heparin that works by blocking certain natural substances in the blood that cause clotting.

How is this Eugia Us Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 55150023202. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
55150-232-02
11-Digit CMS (5-4-2)
55150-0232-02

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.